Teprotumumab-related Cutaneous Hypersensitivity Reactions

Area of Science:

• Immunology
• Dermatology
• Ophthalmology

Background:

• Thyroid eye disease (TED) is an autoimmune condition affecting the eye socket.
• Teprotumumab is a novel monoclonal antibody treatment for TED, targeting the IGF-1R pathway.
• Understanding treatment-related adverse events is crucial for patient safety and therapeutic management.

Purpose of the Study:

• To report and characterize cutaneous hypersensitivity reactions associated with teprotumumab therapy in patients with thyroid eye disease.
• To investigate the potential immunogenic nature of teprotumumab based on observed cutaneous reactions.
• To emphasize the need for vigilant monitoring during teprotumumab treatment.

Main Methods:

• Retrospective case series analysis of four patients diagnosed with thyroid eye disease.
• Detailed clinical observation and documentation of adverse events during teprotumumab infusions.
• Correlation of reaction onset with the timing of teprotumumab administration.

Main Results:

• Four cases of cutaneous hypersensitivity reactions were identified during teprotumumab treatment.
• Reactions manifested between the second and fifth infusions across all reported cases.
• The observed reactions suggest a potential immune-mediated response to the monoclonal antibody.

Conclusions:

• Cutaneous hypersensitivity reactions are a notable adverse event during teprotumumab therapy for thyroid eye disease.
• These reactions may indicate an immunogenic component of teprotumumab, necessitating careful consideration.
• Close clinical monitoring for skin reactions is essential throughout the treatment course to ensure patient safety.